World Malaria Day 2023: Scientists have made a new vaccine for ‘Malaria’. Which is being considered as ‘world changer’. It is called R21/Matrix-M. This malaria vaccine is the first such vaccine in the world which has crossed the target of 75 percent efficacy of ‘World Health Organization’. On one hand, WHO i.e. ‘World Health Organization’ is considering approving this vaccine. At the same time, Ghana has become the first country in the world to have approved this vaccine. This vaccine has been made by Oxford University of London. The Food and Drugs Authority of Ghana has also approved this vaccine for children aged 5-36 months. Children of this age are more at risk of diseases like malaria.
What did Oxford University say about this new malaria vaccine?
According to Oxford University, it is expected that this will be the first such important step. When Ghana and African children will be able to fight malaria through this vaccine. Professor Adrian Hill, Chief Investigator of the R21/Matrix-M Vaccine Program and Director of the University’s Jenner Institute, said: ‘This is the culmination of 30 years of malaria vaccine research at Oxford, with the design and provision of a high efficacy vaccine .
This vaccine can be supplied in sufficient quantity to those countries which need it the most. The researchers published their findings from the Phase IIB trial of the vaccine in the journal ‘SSRN/Preprints with The Lancet’, which demonstrated a high-level efficacy of 77 per cent at a 12-month follow-up.
What did the researcher say about the dose of this vaccine?
Researchers reported vaccine efficacy of 77 percent in the high-dose adjuvant group and 71 percent in the low-dose adjuvant group, with no serious vaccine-related adverse events recorded at 12 months of follow-up.
More than 100 malaria vaccine candidates have entered clinical trials over the past few decades, but none of them have shown efficacy above 75 percent, as targeted by the WHO’s Malaria Vaccine Technology Roadmap.
‘Serum Institute of India’ will work to make this vaccine
‘Serum Institute of India’ Biotechnology giant which is manufacturing R21 vaccine. He said it has the capacity to manufacture more than 200 million doses annually. Adar Poonawalla, CEO of the Serum Institute, as quoted by ‘The Guardian’, said the licensing of the vaccine by the Ghanaian authorities is an important milestone in the fight against malaria.
read this also: Gold, silver, copper, bronze… what to eat in which utensil so that it will work like nectar in the body, here is the answer
Check out below Health Tools-
Calculate Your Body Mass Index (BMI)